As European markets rally following a U.S.-Iran ceasefire, investors are increasingly focusing on opportunities that offer both stability and income in the form of dividends. In such an environment, dividend stocks can be appealing for their potential to provide steady returns amidst economic uncertainties.

As European markets navigate volatility amid AI disruption concerns and digest strong U.S. job data, the pan-European STOXX Europe 600 Index managed to hit a new high, reflecting resilience in the region's economy. In such an environment, dividend stocks can offer investors a measure of stability and income potential, making them an attractive consideration for those looking to balance growth with steady returns.

The European market has shown resilience, with the STOXX Europe 600 Index gaining ground amid positive economic data and mixed earnings results across major stock indexes. In this dynamic environment, dividend stocks can offer a steady income stream and potential stability, making them an appealing option for investors seeking to navigate the current market conditions.

If you’re wondering what to do with Mota-Engil SGPS stock, you’re definitely not alone. With shares up an outstanding 131.0% over the past year and an incredible 425.1% gain over the last three years, investors are right to question if the growth story still has room to run. Just in the past week, the stock surged another 13.0%. Part of this can be traced back to a wave of positive market sentiment in the infrastructure and construction sectors, fueled by hefty contract wins across Southern...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.